Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions for maintaining intracellular osmolarity, acid-base balance, and cellular metabolism. Dextrose 5% supplies calories and water for hydration. Sodium chloride 0.3% supplies sodium and chloride ions for extracellular fluid volume and electrolyte balance.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Treatment of potassium deficiency when hypokalemia is present or to prevent hypokalemia in patients who cannot tolerate oral potassium,Maintenance of fluid and electrolyte balance,Total parenteral nutrition or as a source of calories
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
10-40 m Eq potassium chloride intravenously, rate not exceeding 10 m Eq/hour or 200 m Eq/24 hours, based on serum potassium levels.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Terminal half-life approximately 1-2 hours for plasma potassium; clinical effect persistence depends on total body potassium deficit.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Potassium is primarily excreted by the kidneys. Dextrose is metabolized to carbon dioxide and water via glycolysis and the citric acid cycle. Sodium and chloride are not metabolized but are excreted renally and via sweat.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal excretion >90% as potassium ion; minimal biliary/fecal (<5%).
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
0% (potassium is not protein-bound).
Low protein binding; 0–11% bound, primarily to albumin.
0.5-0.7 L/kg; potassium is predominantly intracellular, with <2% in extracellular fluid.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100%; oral: approximately 90-100% (not applicable to this IV formulation).
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25-50%; GFR < 10 m L/min: avoid or reduce dose by 50-75% with close monitoring.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% and monitor potassium levels.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
0.5-1 m Eq/kg/dose intravenously, maximum rate 0.5 m Eq/kg/hour, maximum concentration 40 m Eq/L, with caution.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Initiate at lower end of dosing range (10-20 m Eq), maximum infusion rate 5-10 m Eq/hour, monitor renal function and serum potassium closely.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Potassium chloride injection must be diluted and administered slowly via infusion to avoid fatal hyperkalemia. Concentrated potassium solutions are for intravenous use only after dilution. Do not administer undiluted.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of hyperkalemia, especially in patients with renal impairment, adrenal insufficiency, or receiving potassium-sparing diuretics,Monitor serum potassium, glucose, and electrolytes; adjust infusion rate accordingly,Use with caution in patients with heart disease, metabolic acidosis, or conditions predisposing to hyperglycemia,Extravasation may cause tissue necrosis
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperkalemia,Severe renal impairment with oliguria or anuria,Acute dehydration,Uncontrolled Addison's disease,Adynamia episodica hereditaria,Concomitant use of potassium-sparing diuretics, ACE inhibitors, or ARBs without close monitoring
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, tomatoes, potatoes, spinach, dried fruits, legumes) and potassium-containing salt substitutes. No other specific food interactions.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Potassium chloride is a normal constituent of body fluids and is not teratogenic at physiological doses. No fetal risks have been associated with intravenous potassium administration when used appropriately for correction of hypokalemia. Excessive potassium levels (hyperkalemia) can cause maternal cardiac arrhythmias, which may secondarily affect fetal oxygenation, but direct teratogenicity is not documented. Use during any trimester is considered safe if indicated, provided maternal serum potassium is monitored to maintain normal levels.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Potassium is a normal component of breast milk and is secreted at levels that do not pose a risk to the nursing infant. No specific M/P ratio is available because endogenous potassium levels are tightly regulated. Supplementation to correct maternal hypokalemia is compatible with breastfeeding; excessive intake could theoretically cause hyperkalemia in the infant but is not a concern with intravenous administration at standard doses.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy-induced hypervolemia and increased glomerular filtration rate (GFR) may slightly increase potassium requirements, but no standard dose adjustment is recommended for potassium chloride. Dosing should be individualized based on serum potassium levels and renal function. In preeclampsia or renal impairment, lower doses may be needed to avoid hyperkalemia.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
This is a hypertonic solution (dextrose 5%, Na Cl 0.3%) providing potassium supplementation. Administer via central line if concentration exceeds peripheral vein tolerance (typically >10 m Eq/100 m L). Monitor serum potassium and ECG during infusion; rate should not exceed 10-20 m Eq/hour in non-emergent settings. Contraindicated in severe hyperkalemia, anuria, or untreated Addison's disease.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Report any pain, redness, or swelling at the IV site immediately.,Inform your healthcare provider if you have a history of kidney problems, heart disease, or are taking potassium-sparing diuretics.,Do not consume potassium-rich foods or salt substitutes without consulting your doctor.,This medication is given intravenously; you may need frequent blood tests to monitor your potassium levels.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions for maintaining intracellular osmolarity, acid-base balance, and cellular metabolism. Dextrose 5% supplies calories and water for hydration. Sodium chloride 0.3% supplies sodium and chloride ions for extracellular fluid volume and electrolyte balance.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is: 10-40 m Eq potassium chloride intravenously, rate not exceeding 10 m Eq/hour or 200 m Eq/24 hours, based on serum potassium levels.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride is a normal constituent of body fluids and is not teratogenic at physiological doses. No fetal risks have been associated with intravenous potassium administrati. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.